image credit- freepik
China-based Sanyou Biopharmaceuticals and NovoCodex Biopharmaceuticals have jointly announced that the two companies have formally entered into a strategic collaboration agreement.
The partnership will focus on the joint development of innovative antibody-drug conjugates (ADCs), leveraging Sanyou Bio's strengths in innovative ADC discovery powered by its AI-Super trillion antibody/molecule libraries (AI-STAL) and Sanyou AI-Drug Accelerator (SAI-DA), together with NovoCodex's extensive expertise in site-specific conjugation technology using unnatural amino acids.
Through this collaboration, the two companies will jointly advance the development of innovative ADC therapeutics and work to deliver therapies with greater clinical value to cancer patients worldwide.
Sanyou Bio will leverage the AI-STAL platform to screen antibody candidates with high internalisation efficiency and high target specificity, while NovoCodex will use the NovoCode™ platform to develop site-specific conjugation processes, establishing a coordinated evaluation of antibody characteristics and conjugation strategies from the outset.
Combining Sanyou Bio's molecular design capabilities with NovoCodex's site-specific conjugation platform, the two companies will advance the evaluation of target combinations for dual-target ADCs, the screening of payload pairs for dual-payload ADCs, and preclinical proof-of-concept studies.
The two companies will establish joint project teams to integrate the entire development process, from target research and antibody screening through conjugation process development and in vitro and in vivo evaluation, thereby accelerating the development of ADC candidates.
